Phase 1/Pilot Consortium

2015

**ADVL1011 – Ruxolitinib**

**ADVL1014 – Reolysin**

**ADVL0911 – Seneca Valley Virus (NTX-010)**

**ADVL0813 – Cixutumumab (IMC-A12) + Temsirolimus (CCI-779)**

**ADVL1114 – Temsirolimus (CCI-779) with Intensive Re-induction Abstract**

**ADVL1212 – Crizotinib with Conventional Chemotherapy Abstract**
Phase 1/Pilot Consortium

**ADVL1213 – Ontuxizumab (MORAb-004) Abstract**

**AHOD1221 – Brentuximab Vedotin + Gemcitabine Abstract**
Phase 1/Pilot Consortium

2014

**ADVL0918 – Temsirolimus + Irinotecan and Temozolomide**

**ADVL1013 – MK-2206**

**ADVL1011 – Ruxolitinib Abstract**

**ADVL1111 – Tivantinib (ARQ 197) Abstract**

**ADVL1211 – Cabozantinib (XL184) Abstract**
Phase 1/Pilot Consortium

2013

**ADVL1112 – Imetelstat**

**ADVL0912 – Crizotinib**

**ADVL0819 – Vorinostat and Temozolomide in CNS Tumors**

**ADVL0815 – Pazopanib**

**ADVL0911 – Seneca Valley Virus (NTX-010) Abstract**
Phase 1/Pilot Consortium

ADVL1014 – Reolysin Abstract

ADVL1115 – Trebananib (AMG386) Abstract
Phase 1/Pilot Consortium

2012

ADVL0916 - Vorinostat and Bortezomib

ADVL0812 - MLN8237

ADVL0714 - VEGF Trap

ADVL0712 – Cixutumumab (IMC-A12)

ADVL0612 – Sunitinib Pharmacokinetics

ADVL0413 – Sorafenib
Phase 1/Pilot Consortium

ADVL1013 – MK 2206 Abstract

ADVL0918 – Temsirolimus + Irinotecan and Temozolomide Abstract

ADVL0912 – Crizotinib Abstract

ADVL0813 – Cixutumumab (IMC-A12) + Temsirolimus Abstract
Phase 1/Pilot Consortium

2011

**ADVL0612 – Sunitinib**

**ADVL0516 – Dasatinib**

**ADVL0516 – Dasatinib Correlative study**

**ADVL0515 – Vinblastine + Carboplatin in Low Grade Glioma**

**ADVL0419 – Valproic Acid**

**ADVL0319 – Lenalidomide**

**ADVL0116 – Tipifarnib**
Phase 1/Pilot Consortium

**ADVL0916 – Vorinostat and Bortezomib Abstract**

**ADVL0819 – Vorinostat and Temozolomide Abstract**

**ADVL0815 – Pazopanib Abstract**

**ADVL0815 – Pazopanib Abstract**

**ADVL0813 – Cixutumumab (IMC-A12) + Temsirolimus Abstract**

**ADVL0612 – Sunitinib Abstract**
Phase 1/Pilot Consortium

**Phase 1 Correlatives Studies - Antiangiogenesis Biomarkers Abstract**
Phase 1/Pilot Consortium

2010

**ADVL0812 - MLN8237 Correlative Study**

**ADVL0517 – Ispenisib**

**ADVL0416 – Vorinostat**

**ADVL0414 – Vincristine + Irinotecan + Temozolomide**

**ADVL0215 – Decitabine + Doxorubicin and Cyclophosphamide**

**ADVL08N1 - Participation in Pharmacokinetic Studies**

**P9423 – Valspodar (PSC833)**
Phase 1/Pilot Consortium

**ADVL0812 - MLN8237 Abstract**

**ADVL0714 - VEGF Trap Abstract**

**ADVL0515 - Vinblastine + Carboplatin Abstract**
Phase 1/Pilot Consortium

2009

ADV10415 – Oxaliplatin and Irinotecan

A0935 – ch14.18 + GM-CSF and IL-2

P9973 (POG-9973) – Imatinib Pharmacokinetics

P9376 (POG 9376) – Taxol (Paxlitaxel) and Ifosfamide

ADV10712 – Cixutumumab (IMC-A12) Abstract

ADV10414 – Vincristine + Irinotecan + Temozolomide Abstract
Phase 1/Pilot Consortium

**ADVL0414 – Vincristine + Irinotecan + Temozolomide Abstract**

**ADVL0413 – Sorafenib Abstract**

**ADVL0319 – Lenalidomide Abstract**
Phase 1/Pilot Consortium

2008

**ADVL0314 - Bevacizumab**

**ADVL0214 – Erlotinib**

**ADVL0011 – Temozolomide and Lomustine in HGGs**

**A09712 – Motexafin gadolinium**

**A0003 – Arsenic Trioxide in ALL**

**0903 (CCG 0903) – Taxol (Paxlitaxel) in ALL**

**P9870 (POG-9870) – O6BG and BCNU**
Phase 1/Pilot Consortium

Phase 1 Studies - Irinotecan Pharmacokinetics

ADVL0612 – Sunitinib Abstract

ADVL0517 – Ispinesib Abstract

ADVL0516 – Dasatinib Abstract

ADVL0416 – Vorinostat Abstract

ADVL0319 – Lenalidomide Abstract

ADVL0319 – Lenalidomide Correlative Study Abstract
Phase 1/Pilot Consortium

**ADVL0215 – Decitabine + Doxorubicin and Cyclophosphamide Abstract**

**ADVL0012 – Cereport (Labradimil) and Carboplatin Abstract**
Phase 1/Pilot Consortium

2007

ADVLO411 - Temozolomide in ALL

ADVLO317 – Bortezomib in ALL

ADVLO316 – 17-AAG

ADVLO311 – Pemetrexed

ADVLO211 – G3139

ADVLO016 – Gefitinib Correlative studies

ADVLO013 (CCG number-A0998) – 90Y-IT + Rituximab
**Phase 1/Pilot Consortium**

**ADVL0516 – Dasatinib Abstract**

**ADVL0416 – Vorinostat Abstract**

**ADVL0415 – Oxaliplatin and Irinotecan Abstract**

**ADVL0414 – Vincristine + Irinotecan + Temozolomide Abstract**

**ADVL0215 – Decitabine + Doxorubicin and Cyclophosphamide Abstract**
Phase 1/Pilot Consortium

2006

**ADVL0212 – Depsipeptide**

**ADVL0018 (CCG-A0981) – hu14.18-IL2**

**P9772 (POG-9772) – MGI 114**

**CCG-09709 (POG-9709) – Fenretinide**

**0936 (CCG-0936) – Vinorelbine**

**ADVL0317– Bortezomib in ALL Abstract**
ADVL0316 – 17-AAG Abstract

ADVL0314 – Bevacizumab Abstract

ADVL0311 – Pemetrexed Abstract

ADVL0214 – Erlotinib Abstract

ADVL0018 (CCG-A0981) – hu14.18-IL2 Abstract

ADVL0013 (CCG number-A0998) – 90Y-IT + Rituximab Abstract
Phase 1/Pilot Consortium

2005

**ADVL0017 (CCG-A0972) – Flavopiridol**

**ADVL0016 – Gefitinib**

**ADVL0012 – Cereport (Labradimil) and Carboplatin**

**A09717 (CCG-09717) – Thrombopoietin + G-CSF Following ICE**

**P9972 (POG P9972) – Trabectedin**

**POG 9879 – Cyclosporine A, VP-16, Vcr + XRT in BSG**

**POG 9779 – Ralitrexed in ALL**
Phase 1/Pilot Consortium

**ADVL0411 - Temozolomide in ALL Abstract**

**ADVL0215 – Decitabine + Doxorubicin and Cyclophosphamide Abstract**

**ADVL0212 – Depsipeptide Abstract**

**ADVL0211 – G3139 Abstract**

**ADVL0017 (CCG-A0972) – Flavopiridol Abstract**

**ADVL0013 (CCG number-A0998) – ^90^Y-IT + Rituximab Abstract**
Phase 1/Pilot Consortium

2004

**ADVL0115** – Bortezomib

**P9973** (POG-9973) – Imatinib in PH+ Leukemia

**P9870** (POG-9870) – O6BG and BCNU Pharmacokinetics

**9675** (POG-9675) – Tirapazamine and Cyclophosphamide

**ADVL0018 (CCG-A0981)** - hu14.18-IL2 Abstract

**ADVL0016** – Gefitinib Abstract
Phase 1/Pilot Consortium

**ADVL0013 (CCG number-A0998) – 90Y-IT + Rituximab Abstract**

**ADVL0011 – Temozolomide and Lomustine in HGGs Abstract**
**Phase 1/Pilot Consortium**

**2003**

**P9970 (CCG-P9970) – Cisplatin and Irinotecan**

**POG 9670 – Rebeccamycin**

**POG 9573 – Taxol (Paclitaxel)**

**2002**

**X0942 (CCG-0942) – Topotecan and Cisplatin**

**POG 9579 - Doxil**

**POG 9575 - Topotecan**

**POG 9571 – Irinotecan Case report**
Phase 1/Pilot Consortium

2001

POG 9571 – Irinotecan